Home BancShares Inc

Home BancShares Inc (HOMB) News & Events

$29.370

-0.021 (-0.07%)At close

HOMB News

HOMB Events

10/21 17:30

Home BancShares Increases Share Repurchase Authorization to 20 Million

Home BancShares increased the number of shares authorized for repurchase under the company's stock repurchase program. On October 16, the board increased the number of shares of the company's common stock authorized for repurchase under its stock repurchase program to 20M shares. As of October 16, 2026, approximately 13,450,123 shares remained available under the existing authorization; therefore, the Board's action increased the number of shares available for repurchase by 6,549,877.

10/14 20:00

Investor Sentiment Hit by Bond Market, Oracle Shares Down 9%

Investor sentiment buckled under a one-two punch from fixed income markets on Wednesday.  Hotter than expected CPI inflation data goosed up Treasury yields, with the 10-year spiking to 5.30% and Fed Funds futures pricing in a higher probability of more FOMC tightening.  CME Fed Funds tool estimates October hike at 32% vs. 22% prior and the case for two more consecutive hikes this year at 26% vs. 19% prior.  Then, headlines concerning the corporate bond market spooked investors further as CoreWeave'sunsecured notes due 2032 slid below 80 cents on the dollar, a level broadly viewed as a distress marker, compounding the recent pressure seen in the Tech space.  Oracle, one of the more heavily indebted AI buildout linked names, ended the day down 9% at the lowest level since August.Technology was by far the worst-performing sector in the S&P 500, balanced by the defensively-oriented Consumer Staples and Healthcare.  Tech-heavy Nasdaq Composite ended the day down 2% at the lowest level in nearly a month.  Cautious tone is extending into the evening session - in the opening hours, S&P e-minis are down 0.2% and the Nasdaq 100 contract is down by 0.7%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Rezoluteup 5.9% after completing enrollment in study of ersodetugViking Therapeuticsup 1.4% after being initiated at Buy by UBSDOWN AFTER EARNINGS -Home BancSharesdown 2.5%Equity Bancsharesdown 1.4%ALSO LOWER -Rocket Labdown 6.6% after delaying Neutron launch to 2027 from Q4Spotify Technologydown 1% after downgrade to Hold at StoneXAlbertsons Companiesdown 0.8% after downgrade to Neutral at Goldman Sachs

10/14 17:30

Q3 Revenue at $288.4M, Below Consensus

Reports Q3 revenue $288.4M, consensus $294.1M. Reports Q3 net interest margin: 4.53% vs 4.56% y/y.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading